What is HEPHAISTOS-Pharma?
HEPHAISTOS-Pharma is a preclinical stage biotechnology company headquartered in Orsay, Ile-de-France, France. The company is dedicated to developing next-generation oncology therapies designed to harness the power of the immune system to treat previously incurable cancers. Their focus on innovative immunotherapies underscores a commitment to addressing unmet medical needs in cancer treatment.
How much funding has HEPHAISTOS-Pharma raised?
HEPHAISTOS-Pharma has raised a total of $13.1M across 1 funding round:
Angel/Seed
$13.1M
Angel/Seed (2024): $13.1M with participation from European Investment Centre, Noshaq, Fournier-Majoie Foundation, and Bpifrance
Key Investors in HEPHAISTOS-Pharma
European Investment Centre
The European Investment Centre is a financial institution operating an investment fund platform, providing infrastructure for investment advisors and firms to manage client accounts and distribute funds across borders. Their involvement suggests a strategic interest in supporting European innovation.
Noshaq
Noshaq is a Liège-based investment fund focused on financing the creation and growth of businesses, particularly those offering new socio-economic perspectives in its region. Their investment in HEPHAISTOS-Pharma indicates a commitment to fostering innovative enterprises.
Fournier-Majoie Foundation
The Foundation Fournier-Majoie is dedicated to combating cancer through venture philanthropy, funding and supporting promising oncology research projects. Their participation highlights a direct alignment with HEPHAISTOS-Pharma's mission to develop novel cancer treatments.
What's next for HEPHAISTOS-Pharma?
The recent major enterprise-level funding and strategic investment signal a critical growth phase for HEPHAISTOS-Pharma. This capital infusion is expected to accelerate the company's preclinical development pipeline, potentially enabling further research, clinical trial preparations, and strategic partnerships. The backing from prominent investors suggests strong confidence in the company's scientific approach and its potential to disrupt the oncology landscape.
See full HEPHAISTOS-Pharma company page
